Rocket Pharmaceuticals (RCKT) Share-based Compensation (2014 - 2026)

Rocket Pharmaceuticals has disclosed Share-based Compensation across 13 years of filings, most recently posting $8.5 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $8.5 million, down 17.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.2 million (down 19.95% YoY), and the FY2025 annual result was $37.1 million, down 15.62% from the prior year.
• Share-based Compensation came in at $8.5 million for Q1 2026 at Rocket Pharmaceuticals, up from $6.1 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $11.3 million in Q2 2024 to a low of $6.1 million in Q4 2025.
• The 5-year median for Share-based Compensation is $9.9 million (2023), against an average of $9.4 million.
• Across the five-year window, Share-based Compensation jumped 42.19% in 2023 and plunged 44.88% in 2025, its largest moves.
• Rocket Pharmaceuticals' Share-based Compensation stood at $9.7 million in 2022, then climbed by 2.45% to $9.9 million in 2023, then rose by 11.66% to $11.1 million in 2024, then sank by 44.88% to $6.1 million in 2025, then jumped by 38.96% to $8.5 million in 2026.
• The last three Share-based Compensation figures came in at $8.5 million (Q1 2026), $6.1 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.